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Abstract The organic anion transporting polypeptides
(rodents: Oatps, human: OATPs) form a superfamily of
sodium-independent transport systems that mediate the
transmembrane transport of a wide range of amphipathic
endogenous and exogenous organic compounds. Since the
traditional SLC21 gene classification does not permit an
unequivocal and species-independent identification of
genes and gene products, all Oatps/OATPs are newly
classified within the OATP/SLCO superfamily and sub-
divided into families (40% amino acid sequence
identity), subfamilies (60% amino acid sequence iden-
tity) and individual genes and gene products according to
their phylogenetic relationships and chronology of iden-
tification. Implementation of this new classification and
nomenclature system occurs in agreement with the
HUGO Gene Nomenclature Committee (HGNC). Among
52 members of the OATP/SLCO superfamily, 36 mem-
bers have been identified so far in humans, rat and mouse.
The latter are clustered within 6 (out of 12) families
(OATP1–OATP6) and 13 subfamilies. Oatps/OATPs
represent 12 transmembrane domain proteins and contain
the superfamily signature D-X-RW-(I,V)-GAWW-X-G-
(F,L)-L. Although species divergence, multispecificity
and wide tissue distribution are common characteristics of
many Oatps/OATPs, some members of the OATP/SLCO
superfamily are highly conserved during evolution, have a
high substrate specificity and exhibit unique cellular
expression in distinct organs. Hence, while Oatps/OATPs
with broad substrate specificity appear to play an
important role in the bioavailability, distribution and
excretion of numerous exogenous amphipathic organic
anionic compounds, Oatps/OATPs with a narrow spec-
trum of transport substrates may exhibit more specific
physiological functions in distinct organs.
Keywords Bile salt · Drug transporter · Xenobiotic
elimination
Introduction
Organic anion transporting polypeptides (rodents: Oatps,
human: OATPs) are important membrane transport pro-
teins that mediate the sodium-independent transport of a
wide range of amphipathic organic compounds including
bile salts, organic dyes, steroid conjugates, thyroid
hormones, anionic oligopeptides, numerous drugs and
other xenobiotic substances [1]. Although some Oatps/
OATPs are selectively involved in the hepatic clearance
of albumin-bound compounds from portal blood plasma
[2], most Oatps/OATPs are expressed in multiple tissues
including the blood-brain barrier (BBB), choroid plexus,
lung, heart, intestine, kidney, placenta and testis [3].
Unfortunately, the rapid and independent identification of
new Oatps/OATPs has led to the assignment of either
different names for identical proteins or similar names for
non-orthologous gene products [1]. Furthermore, the
current classification within the solute carrier family 21
(rodents: Slc21; human: SLC21) does not permit an
unequivocal and species-independent identification of the
various Oatp/OATP-genes [1]. To solve these problems
and to avoid further confusions in future scientific
discussions, we have proposed a new species-independent
classification and nomenclature system that is based on
divergent evolution and defines an Oatp/OATP-gene
superfamily, which can be divided further into families,
subfamilies and individual genes and gene products
according to the evolutionary relationships and the degree
of amino acid sequence identities [1]. Meanwhile, the
principle of this evolutionary-based new Oatp/OATP
classification and nomenclature system has been wel-
comed and accepted by several experts in the field and,
most importantly, also by the HUGO Gene Nomenclature
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Committee (HGNC). Since the current Slc21/SLC21
classification does not permit the sub-classification of
the Oatp/OATP-gene superfamily into families and sub-
families as suggested in analogy to the cytochrome P450
superfamily [1, 4], and since the HGNC suggested to keep
the root gene symbol “SLC”, it has been agreed to create
the new “SLCO” symbol for gene classification and to
keep the “OATP” symbol for corresponding protein
nomenclature. It is the main purpose of this overview to
present the definite principles, rules and naming of the
new OATP/SLCO classification and nomenclature sys-
tem. Furthermore, comparative tables and figures are
provided to help in the translation of the old into the new
system. And finally, the history of discovery and the
molecular and physiological properties of individual
Oatps/OATPs will be summarized. Further details about
the molecular and functional properties of this transporter
superfamily can be found in our previous review [1].
New classification and nomenclature
So far 36 Oatps/OATPs have been identified in humans,
rat and mouse (Fig. 1). As indicated in Table 1, most
Oatps/OATPs have been given several different trivial
names, and sometimes similar names have been used for
different gene products in different species (e.g. rat
Oatp1/human OATP1; rat Oatp2/mouse Oatp2/human
OATP2). Furthermore, organ-specific rather than a func-
tionally based nomenclature has been used despite
incomplete knowledge about the organ topology of
individual Oatps/OATPs (Table 1). Although the provi-
sional use of continuous numbering of rodent Oatps,
alphabetic ordering of human OATPs and gene classifi-
cation within the Slc21/SLC21 system has helped in the
clear-cut identification of a specific gene product in the
past, this system permits neither unequivocal and species-
independent protein and gene identifications nor the
classification of the various Oatp/OATP genes within a
separate transporter superfamily [1]. That all Oatps/
OATPs do indeed form a transporter gene superfamily
is evidenced by the phylogenetic tree (Fig. 1) and its
underlying amino acid sequence identities [1]. This
OATP superfamily can be further subdivided into families
and subfamilies in close analogy to the classification of
drug-metabolizing enzymes [4, 5]. Hence, Oatps/OATPs
within the same family share 40% amino acid sequence
identities and are designated by Arabic numbering, e.g.
families OATP1, OATP2, OATP3, OATP4, OATP5 and
OATP6 (Fig. 2). Individual subfamilies include Oatps/
OATPs with amino acid sequence identities 60% and
are designated by letters, e.g. subfamilies OATP1A,
OATP1B, OATP1C, OATP2A, OATP2B, OATP3A etc.
If there are several individual gene products (proteins)
within the same subfamily, additional continuous Arabic
numbering based on the chronology of identification
should be used, e.g. Oatp1a1, OATP1A2, Oatp1a3, etc.
(Fig. 2).
While the above outlined classification principle has
been accepted by several experts in the field (number of
experts contacted: 16; positive responses: 8; negative
responses: 0; no responses: 8) and by the HGNC, the
latter suggested to keep the “SLC” symbol for gene
identification and to use the functional “OATP” symbol
for protein nomenclature. To follow this recommendation
it was necessary to introduce a new gene symbol, since
the SLC21 stem is not compatible with an unambiguous
family designation, e.g. the gene of the OATP1 family
member OATP1A2 would become SLC211A2, which
could be confused with a member of the (hypothetical)
SLC211 gene family. This problem was solved by
changing SLC21 into the new gene symbol “SLCO”
(O = initial letter of OATP), which classifies for example
the gene of OATP1A2 unambiguously as SLCO1A2
(Figs. 2, 3). By this adaptation it is possible to use the
same phylogenetically based, species-independent and
open-ended classification/nomenclature system at both
the protein and gene levels for all members of the OATP/
SLCO superfamily [1], to stay within the SLC transporter
gene classification of the HUGO (http://www.gene.ucl.
ac.uk/nomenclature/) and mouse (http://www.informatics.
jax.org) gene nomenclature committees, and to keep the
original and well-accepted functional OATP designation
at the protein level.
The principles and consequences of the new OATP/
SLCO classification and nomenclature system are further
illustrated in Figs. 2 and 3 {Please note the change
introduced in Fig. 3 (see legend) with respect to the
classification of the families OATP6 and OATP10 as
compared to our previous suggestion [1]}. Furthermore,
the old and new protein and gene nomenclatures are
compared in Table 2 and Fig. 3 to help in the translation
from the old into the new system. Unambiguous and
species-independent classification and naming of newly
identified proteins (genes) of the OATP/SLCO superfam-
ily according to the new system must include: (1) the
superfamily designation OATP (SLCO) (human mem-
bers) or Oatp (Slco) (rodent members), (2) the family
number, (3) the subfamily letter (capital letters for human
members, small letters for rodent members), and (4)
continuous Arabic numbering according to the chronol-
ogy of protein (gene) identification. Human proteins
(genes) are given in capitals [e.g. OATP1A2 (SLCO1A2)]
(http://www.gene.ucl.ac.uk/nomenclature/), while rat and
mouse proteins (genes) are indicated by an initial capital
followed by small letters [e.g. Oatp1a1 (Slco1a1),
Oatp7a1 (Slco7a1)] (http://www.informatics.jax.org).
For other animal species (e.g. farm animals such as
cow, pig, cat, dog, chicken) the exact writing styles
should follow the recommendations of the respective
nomenclature committees (e.g. http://www.thearkdb.org/
nomenclature.html; for further links see http://www.
gene.ucl.ac.uk/nomenclature/). Furthermore, if several
splice variants of a given Slco/SLCO gene are known,
the names of the resulting Oatps/OATPs should be
followed by an underscore, the lower case letter “v” and
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the consecutive numbering of the variants (e.g. Oat-
p1a3_v1, Oatp1a3_v2; Table 2).
The above outlined new classification system takes
into account the molecular and phylogenetic relationships
between individual genes and proteins, is easy to follow
and provides an unambiguous open-ended species-inde-
pendent nomenclature for all members of the OATP/
SLCO superfamily. Implementation of the new classifi-
Table 1 Current Oatp/OATP protein and gene nomenclature and
classification. Ambiguous protein names (e.g. similar names for
distinct proteins, tissue specific names) are highlighted in bold.
Abbreviations: BSAT, brain specific anion transporter; GST, gonad
specific transporter; lst/LST, liver specific transporter; MJAM,
derived from the researchers initials; Oatp/OATP, organic anion
transporting polypeptide; PGT, prostaglandin transporter; Slc/SLC,
solute carrier; TST, testis-specific transporter
Protein
name
Alias Human gene
symbol
Rat gene
symbol
Mouse Gene
Symbol
Oatp1 Oatp – Slc21a1 Slc21a1
PGT hPGT (human), rPGT (rat), mPGT (mouse) SLC21A2 Slc21a2 Slc21a2
OATP-A OATP,OATP1 SLC21A3 – -
OAT-K1 – Slc21a4 -
Oatp2 – Slc21a5 Slc21a5
OATP-C LST-1,OATP2, OATP6 SLC21A6 – -
Oatp3 – Slc21a7 Slc21a7
OATP8 LST-2 SLC21A8 – -
OATP-B OATP-RP2 (human), moat1 (rat), Oatp9 SLC21A9 Slc21a9 -
Oatp4 rlst-1(rat),mlst-1(mouse) – Slc21a10 Slc21a10
OATP-D OATP-RP3 (human), Pgt2 (rat), MJAM(mouse), Oatp11 SLC21A11 Slc21a11 Slc21a11
OATP-E OATP-RP1 (human), oatpE (rat), Oatp12 SLC21A12 Slc21a12 -
Oatp5 – Slc21a13 Slc21a13
OATP-F OATP-RP5 (human), BSAT1(rat), Oatp2(mouse), Oatp14 SLC21A14 Slc21a14 Slc21a14
OATP-J OATP-RP4 SLC21A15 – -
Oatp16 TST-1, GST-1 – Slc21a16 Slc21a16
Oatp17 – – Slc21a17
Oatp18 TST-2, GST-2 – Slc21a18 Slc21a18
OATP-I GST SLC21A19 – -
OATP-H SLC21A20 – -
Fig. 1 Phylogenetic tree of the
human and rodent members of
the OATP/SLCO superfamily
using the traditional (old) pro-
tein nomenclature. Human
OATPs are given in capitals
(exception: OAT-K1 represents
a rat protein). Rodent Oatps are
written with an initial capital
followed by small letters. To
distinguish between rat and
mouse proteins, all mouse
Oatps are indicated by “m”. The
tree was calculated using the
ClustalW program
(http://www.ebi.ac.uk/clustalw/)
and visualized using the pro-
gram TREVIEW [54]
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cation/nomenclature system will be supported by the
creation of an OATP/SLCO web site (http://www.kpt.
unizh.ch/oatp/) and by the corresponding adaptation of
the human (http://www.gene.ucl.ac.uk/nomenclature/) and
mouse (http://www.informatics.jax.org) genome nomen-
clature databases as soon as possible. Furthermore, an
expert committee, the members of which will be indicated
on the OATP/SLCO web site, shall be created to help and
supervise the future classification and nomenclature of
newly identified members of the OATP/SLCO superfam-
ily. We suggest starting with the new classification and
nomenclature of the OATP/SLCO superfamily immedi-
ately and in close coordination with the adaptations of the
human and mouse genome nomenclature databases.
During the transition period, where the traditional (old)
protein and gene names are still familiar to most
investigators in the field, the new nomenclature should
be supplemented by the familiar old names, which should
be given in parentheses at the first occurrence in the
text {e.g. OATP1A2 [previously called OATP-A
(SLC21A3)]}. This principle will also be adhered to in
the following sections of this manuscript.
History of discovery
Rat Oatp1a1 [previously called Oatp1 (Slc21a1)] was the
first member of the OATP/SLCO gene superfamily to be
identified by expression cloning using the Xenopus laevis
oocyte system [6]. Subsequently Oatp2a1 [previously
called PGT (Slc21a2)] was identified by Kanai et al. [7].
OATP1A2 [previously called OATP-A (SLC21A3)] was
the first human superfamily member isolated by hybrid-
ization screening from human liver [8]. Subsequently,
additional Oatps/OATPs were identified and character-
ized from various species using homology screening
either by hybridization experiments or in silico (Figs. 2, 3,
Table 2).
Molecular and phylogenetic relationships
Oatps/OATPs represent 12 transmembrane domain (TM)
proteins with common structural features such as (1) a
large extracellular domain between TMs 9 and 10
(extracellular loop 5), which contains many conserved
cysteine residues, (2) the N-glycosylation sites in extra-
cellular loops 2 and 5, and (3) the consensus superfamily
Fig. 2 Phylogenetic classification and new nomenclature of human
and rodent (rat, mouse) members of the OATP/SLCO superfamily
of membrane transporters. Oatps/OATPs with amino acid sequence
identities 40% among each other belong to the same OATP
family (e.g. OATP1, OATP2, OATP3, OATP4, OATP5, OATP6).
Proteins with amino acid sequence identities 60% are grouped
into subfamilies and denoted with a capital letter after the family
number (e.g. OATP1A, OATP1B, OATP1C, OATP2A, OATP2B,
etc.). Individual proteins (genes) are continuously numbered
according to the chronology of their identification. The “Oatp”
(rodents)/“OATP” (human) symbols denote proteins, while the
“Slco”/ “SLCO” symbols indicate the respective genes. Mouse
Oatps are indicated by “m”. The tree was calculated using the
ClustalW program (http://www.ebi.ac.uk/clustalw/) and visualized
using the program TREVIEW [54]. Only the families OATP1 to
OATP6 are indicated, since only these six families contain human
OATPs (see also Fig. 3)
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signature D-X-RW-(I,V)-GAWW-X-G-(F,L)-L at the
border between extracellular loop 3 and TM 6 [1]. Based
on sequence similarities with EST and genomic database
entries, Oatp/OATP-related proteins were identified in
many different species other than in humans, rat and
mouse, including fruitflies (Drosophila melanogaster),
bees (Apis melifera), nematodes (Caenorhabditis ele-
gans), sea urchins (Strongylocentrotus purpuratus), cat-
fish (Ictalurus punctatus), zebrafish (Danio rerio),
pufferfish (Fugu rubripes), frogs (Xenopus laevis), chick-
en (Gallus gallus), cow (Bos taurus) and pig (Sus scrofa).
However, no similarities were found with the sequenced
genomes of bacteria and yeast. With respect to the
evolution of the animal kingdom, Oatps/OATPs were so
far only found in animals that belong to the bilaterians,
i.e. to species that belong to the clade of protostomia (e.g.
arthropods, nematodes) or to the clade of deuterostomia
(e.g. vertebrates, echinoderms).
Fig. 3 Phylogenetic classification and new nomenclature of 52
members of the OATP/SLCO superfamily of membrane trans-
porters. The superfamily is grouped into families (40% amino
acid sequence identity) and subfamilies (60% amino acid
sequence identity) as described in the text. The new gene symbol
of the superfamily is “Slco” (rodents)/“SLCO” (human). For protein
nomenclature the “Oatp” (rodents)/“OATP” (human) symbol is
used. The new nomenclature consists of (1) the superfamily
designation OATP (SLCO) (human members) or Oatp (Slco)
(rodent members), (2) the family number, (3) the subfamily letter
(capital letters for human members, small letters for rodents), and
(4) continuous Arabic numbering of individual proteins (genes)
according to the chronology of identification. For comparison, the
old (current) protein and gene nomenclature is also given.
Superfamily members of human, rat, mouse, cow, Drosophila
and C. elegans are given illustrating the species-independence of
the new classification system. The phylogenetic tree was calculated
using GCG programs PILEUP, DISTANCES and GROWTREE
and visualized using the program TREEVIW [54]. Important
remark: In comparison to our previously suggested classification
[1] the families OATP6 and OATP10 have been exchanged (i.e.
OATP6 = previous OATP10; OATP10 = previous OATP6). By this
change all families containing human OATPs are clustered within
the families OATP1 to OATP6. Families OATP7 to OATP12 do
not contain any human OATPs. It is suggested that in future this
classification should be used rather than the previous one [1], since
we feel that it is advantageous to group all human OATP-
containing families together
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Functional characteristics, physiological importance
and pharmacological implications
Oatps/OATPs are sodium-independent transport systems
[6, 8, 9, 10]. Their transport mechanism appears to be
anion exchange, coupling the cellular uptake of organic
compounds with the efflux of, for example, bicarbonate,
glutathione and/or glutathione-S-conjugates [11, 12, 13,
14]. Although the latter has been demonstrated so far only
for rat Oatp1a1 and Oatp1a4 [previously called Oatp2
(Slc21a5)], it is highly likely that all members of the
OATP superfamily can mediate bidirectional organic
substrate transport, making the overall directionality of
transport dependent on the prevailing local substrate
gradients. Oatp/OATP-mediated organic anion exchange
seems to be pH-dependent and electroneutral [12]. In
addition, it has been demonstrated that the phosphoryla-
tion state of rat Oatp1a1 is important for transport since
extracellular ATP reduces Oatp1a1-mediated BSP trans-
port in rat hepatocytes via phosphorylation at intracellular
serine residues [15].
Most Oatps/OATPs transport a wide spectrum of
amphipathic organic compounds. This broad substrate
specificity was demonstrated first for rat Oatp1a1 [16].
Originally, Oatp1a1 was isolated as a sodium-independent
bromosulfophthalein (BSP) and taurocholate uptake
system of rat liver [6]. Subsequently, extensive functional
characterization in different experimental systems estab-
lished that it can mediate the transport of a wide range of
amphipathic organic compounds including bile salts,
steroid hormones and their conjugates, thyroid hormones,
organic cations such as N-(4,4-azo-n-pentyl)-21-deoxy-
ajmalinium and numerous drugs including the endothelin
receptor antagonist BQ-123, the thrombin inhibitor CRC-
220, the opioid receptor agonists [d-penicillamine 2,5]
enkephalin (DPDPE) and deltorphin II, the angiotensin-
converting enzyme inhibitors enalapril and temocaprilat,
the HMG-CoA reductase inhibitor pravastatin and the
antihistamine fexofenadine [1]. Such a broad and partially
overlapping substrate specificity has also been document-
ed for most other members of the OATP1A- and
OATP1B-subfamilies (Table 2) indicating that they play
an important role, together with the P-glycoproteins
(Mdrs/MDRs) and the multidrug resistance associated
proteins (Mrps/MRPs), in overall drug absorption and
drug disposition.
The broad substrate specificity of many Oatps/OATPs
raises the question as to the common chemical and/or
structural denominators of Oatp/OATP substrates. No
systematic studies have been performed in this direction
so far. However, from the available data it can be
concluded that in general Oatp/OATP substrates are
anionic amphipathic molecules with a rather high molec-
ular weight (>450) and a high degree of albumin binding
under physiological conditions. Based on recent 3D-
QSAR studies a pharmacophore model containing two
hydrogen bond acceptors, one hydrogen bond donor and
two hydrophobic regions was obtained. These character-
istics are met by most Oatp/OATP substrates including
bile salts, steroids and cyclic and linear peptides.
Rifamycin SV and rifampicin are two structurally
related antibiotics that have been shown to interact with
Oatp/OATP-mediated transport. It turns out that rifamy-
cin is a potent inhibitor of all human liver OATPs as well
as of rat Oatp1a1 and Oatp1a4, while rifampicin mainly
inhibits human OATP1B3 [previously called OATP8
(SLC21A8)] and rat Oatp1a4 [17, 18]. These data indicate
that co-administration of a specific OATP-inhibitor could
be used to increase the oral bioavailability of drugs that
otherwise have a high OATP-mediated hepatic first-pass
elimination. Hence, preferential or even selective inhibi-
tion of hepatic Oatps/OATPs has important implications
for drug development and drug therapy.
Although some Oatps/OATPs are preferentially, or
even selectively, expressed in the liver (e.g. Oatp1b2,
OATP1B1, OATP1B3) (Fig. 4), many Oatps/OATPs
exhibit multiple tissue expression (e.g. Oatp1a1, Oatp1a4,
Oatp1a5, OATP1A2, OATP2B1) (Fig. 4, Table 2) [1]. As
indicated in Fig. 4, all liver Oatps/OATPs are localized at
the basolateral (sinusoidal) plasma membrane domain of
hepatocytes. In contrast, in choroid plexus Oatp1a4 is
localized basolaterally whereas Oatp1a1 and/or Oatp1a5
[previously called Oatp3 (Slc21a7)] is (are) localized at
the apical plasma membrane (Fig. 4) [1]. In addition,
Oatp1a1 and Oatp1a5 are also localized at the apical
plasma membrane domains in renal proximal tubular and
intestinal epithelial cells, respectively (Fig. 4). Hence,
while Oatp1a1 appears to be differentially targeted in
different epithelial cells, Oatp1a4 exhibits consistent
basolateral, and Oatp1a3 [previously called OAT-K1
(Slc21a4)] and Oatp1a5 consistent apical, expression in
polar epithelial cells (Fig. 4). The molecular targeting
mechanisms for various Oatps/OATPs in distinct epithe-
lial cells remain to be elucidated.
Properties of individual human (and rodent) OATPs
Family OATP1
Family OATP1 consists of four subfamilies, of which the
three subfamilies OATP1A, OATP1B and OATP1C
contain 17 individual genes in humans, rat and mouse
(Figs. 2, 3).
Subfamily OATP1A
This subfamily contains a single human member,
OATP1A2 (Figs. 2, 3, Table 2), which is a glycoprotein
of 670 amino acids [8] and shares between 66 and 77%
amino acid sequence identity with its rodent orthologs [1].
Although three different transcript variants encoding two
different proteins are deposited in the database, only
OATP1A2 with 670 amino acids has been functionally
analyzed. The existence of the other two variants has been
predicted only in silico. OATP1A2 was originally cloned
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from a human liver cDNA library, but its strongest
expression is in brain [8].
In addition, OATP1A2 is expressed in liver and colon
cancer cells as well as in the human hepatoma cell line
HepG2 [3, 19, 20]. In human liver, OATP1A2 exhibits an
apparent molecular mass of approximately 85 kDa [20],
while in brain capillary endothelial cells (blood-brain
barrier) its apparent molecular mass is ~ 60 kDa because
of incomplete glycosylation [21].
Transport substrates of OATP1A2 include bile salts
and BSP, steroid conjugates, the thyroid hormones T4, T3
and rT3, prostaglandin E2, the endothelin receptor
antagonist BQ-123, the thrombin inhibitor CRC-220, the
opioid receptor agonists DPDPE and deltorphin II,
fexofenadine, certain magnetic resonance imaging con-
trast agents, ouabain, the lipophillic organic cations N-
(4,4-azo-n-pentyl)-21-ajmalinium, rocuronium and N-
methyl-quinine and -quinidine and the cyanobacterial
toxin microcystin [1]. Thus, human OATP1A2 transports
the largest number of amphipathic substrates of all human
OATPs [22]. Its expression at the blood-brain barrier
suggests an important role for OATP1A2 in (1) the
delivery of drugs and neuroactive peptides to the brain,
and (2) the removal of organic metabolites from the brain.
Down-regulation of rodent Oatps has been demonstra-
ted in several models of cholestatic liver diseases [23] and
some of the transcriptional and post-transcriptional reg-
ulatory mechanisms have been investigated [1]. Interest-
ingly, the expression of human OATP1A2 is maintained
or even moderately increased in patients with primary
sclerosing cholangitis [20] suggesting that its expression
might be differently regulated at the transcriptional and
post-transcriptional level as compared to other Oatps/
OATPs.
OATP1A2 has five rat (Oatp1a1 [6], Oatp1a3 [24],
Oatp1a4 [9], Oatp1a5 [25], and Oatp1a6 [previously
called Oatp5 (Slc21a13) (AF053317)] and four mouse
(Oatp1a1 [26], Oatp1a4 [27], Oatp1a5 [10], Oatp1a6 [28])
homologs within the subfamily OATP1A (Figs. 2, 3,
Table 2). As evidenced from their clustering on chromo-
somes 4 and 6 in rat and mouse, respectively, they arose
through several gene duplications after divergence of the
rodent species from man. Except for Oatp1a6, which so
far seems to be an orphan transporter, all members of the
OATP1A-subfamily have been characterized in great
details at the functional level [1].
Subfamily OATP1B
This subfamily has two human members, OATP1B1
[previously called OATP-C (SLC21A6)], and OATP1B3
(Figs. 2, 3, Table 2). OATP1B1 was cloned from human
liver [3, 29, 30, 31] and encodes a 691-amino-acid
glycoprotein. It shares 80% amino acid identity with
OATP1B3, but only 64%/65% identity with its rat/mouse
ortholog Oatp1b2 [previously called Oatp4 (Slc21a10)]
[1]. Expression of OATP1B1 appears to be restricted to
the basolateral (sinusoidal) plasma membrane of hepa-
tocytes [3, 29, 30, 31] (Fig. 4, Table 2). Its apparent
molecular mass is 84 kDa, which is reduced after
deglycosylation to 54 kDa [31]. Its apparent exclusive
Fig. 4 Distribution and polar
expression of Oatps/OATPs in
selected rat and human epithe-
lial tissues. The Oatps/OATPs
from the same subfamily are
labelled with the same color,
unknown potential members are
given in orange
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expression in human liver suggests that OATP1B1 plays a
crucial role in the hepatic clearance of albumin-bound
amphipathic organic compounds.
The transport functions of OATP1B1 have been
characterized in X. laevis oocytes [22, 30] and in stably
transfected HEK-293 cells [3, 29, 31]. Its spectrum of
transport substrates includes bile salts, conjugated and
unconjugated bilirubin, BSP, steroid conjugates, the
thyroid hormones T4 and T3, eicosanoids, cyclic pep-
tides, drugs such as benzylpenicillin, methotrexate,
pravastatin and rifampicin as well as the natural toxins
microcystin and phalloidin [1]. Thus, OATP1B1 exhibits
a similar wide substrate spectrum as the OATP1A-
subfamily members.
Several polymorphisms in the SLCO1B1 (= gene
symbol of OATP1B1; Figs. 2, 3, Table 2) gene have
been described recently [32, 33]. A number of the
identified SLCO1B1 alleles were associated with a
dramatic reduction of Vmax/Km values indicating a
significant decrease of OATP1B1-mediated transport
function. The OATP1B1 variant OATP1B1-L193R has
been shown to be associated with defects in protein
maturation as well as in transport function [34]. Whether
other polymorphisms of SLCO1B1 also result in de-
creased OATP1B1 function in vivo and/or in additional
phenotypic alterations remain to be investigated.
Transcriptional expression of OATP1B1 appears to be
decreased in primary sclerosing cholangitis since these
patients experience a decrease of mRNA levels to about
50% as compared to healthy control livers [35]. In
addition, similar to Oatp1a1 and Oatp1a4, basal expres-
sion of human OATP1B1 is dependent on the liver-
enriched transcription factor HNF-1a [36].
OATP1B3 (Figs. 2, 3, Table 2) was cloned from
human liver and encodes a glycoprotein of 702 amino
acids [37, 38]. It has an apparent molecular mass of
120 kDa, which is reduced after deglycosylation to
65 kDa [38]. Under normal physiological conditions,
OATP1B3 is predominantly, if not exclusively, expressed
at the basolateral plasma membrane of hepatocytes [37,
38] (Fig. 4, Table 2). However, OATP1B3 has been
shown to also be expressed in various human cancer
tissues as well as in different tumor cell lines derived
from gastric, colon, pancreas, gallbladder, lung and brain
cancers [37]. The pathobiological significance of
OATP1B3 expression in human cancer tissues remains
to be investigated.
The spectrum of transport substrates of OATP1B3 was
investigated in X. laevis oocytes and in stably transfected
HEK-293 cells. It includes bile salts, monoglucuronosyl
bilirubin, BSP, steroid conjugates, the thyroid hormones
T3 and T4, leukotriene C4, linear and cyclic peptides, the
cardiac glycosides digoxin and ouabain, the antineoplastic
organic anion methothrexate, the antibiotic rifampicin and
the natural toxins microcystin and phalloidin [1]. Thus,
OATP1B3 has a similar broad substrate specificity as
OATP1B1. However, OATP1B3 also exhibits unique
transport properties such as, for example, for the intestinal
peptide cholecystokinin 8 (CCK-8) [39], the opioid
peptide deltorphin II [22] and the cardiac glycosides
digoxin and ouabain [22].
Hepatic expression of OATP1B3 depends on HNF-1a
[36] as well as on the bile acid nuclear receptor FXR/
BAR [40]. The latter findings indicate that induction of
SLCO1B3 gene expression by bile acids could serve to
maintain hepatic extraction of xenobiotics and peptides
under cholestatic conditions.
In rat and mouse the single ortholog Oatp1b2 [41, 42]
has been identified for the two human OATP1B-subfam-
ily members (Figs. 2, 3, Table 2). Thus, in contrast to the
OATP1A-subfamily, gene duplication in the OATP1B-
subfamily occurred in man after divergence of the rodent
species. Although Oatp1b2 is also mainly expressed in the
liver and is functionally similar to human OATP1B1 and
OATP1B3 [1], our recent preliminary studies indicate that
Oatp1b2 is expressed additionally in the ciliary body
epithelium of the eye.
Subfamily OATP1C
This subfamily contains human OATP1C1 [previously
called OATP-F (SLC21A14)] (Figs. 2, 3, Table 2), which
was isolated from a human brain library [43] and
represents a 712-amino-acid protein that exhibits 85%/
84% amino acid sequence identities with its rat/mouse
ortholog Oatp1c1 [previously called Oatp14 (Slc21a14)].
These three genes form the OATP1C-subfamily (Figs. 2,
3, Table 2). On the mRNA level OATP1C1 is expressed
in brain and testis (Leydig cells) [43] (Table 2).
Although OATP1C1 belongs to the OATP1 family
(Figs. 2, 3), the members of which are paradigmatic for
their high degree of multispecificity, the substrate spec-
trum of OATP1C1 is rather limited [43]. While some
substrates such as BSP, estradiol-17b-glucuronide, es-
trone-3-sulfate and the thyroid hormone T3 are transport-
ed to some extent, OATP1C1 exerts an especially high
transport affinity for T4 (thyroxine) (Km value ~90 nM)
and rT3 (reverse tri-iodothyronine) (Km value ~130 nM).
Hence, it might play an important role in the delivery and
disposition of thyroid hormones in brain and testis, and
thus during brain development.
Rat Oatp1c1 has been isolated from a cDNA library
enriched in mRNAs specific to the blood-brain barrier
[44]. Nothing is known so far about the function and
regulation of this putative organic anion transporter.
Interestingly, however, mouse Oatp1c1 has been isolated
from a cochlea cDNA library (accession number
NM_021471) indicating that it might play a physiological
role in the inner ear.
Family OATP2
Family OATP2 consists of the two subfamilies OATP2A
and OATP2B with a total of five individual genes in man,
rat and mouse (Figs. 2, 3).
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Subfamily OATP2A
This subfamily contains human OATP2A1 [previously
called PGT (SLC21A2)] (Figs. 2, 3, Table 2), which is a
protein of 643 amino acids that shares 82%/83% amino
acid sequence identities with its rat/mouse orthologs [1].
Although OATP2A1 has been cloned from a kidney
library [45], its mRNA is ubiquitously expressed with
highest levels in heart, skeletal muscle and pancreas.
Neither the protein expression nor its transcriptional and/
or post-transcriptional regulations have been studied in
any detail. On the functional level, OATP2A1 has been
characterized in transiently transfected HeLa cells, where
it transported different prostaglandins and thromboxane
B2. Human OATP2A1 has the single ortholog Oatp2a1 in
rat [7] and mouse [46] (Figs. 2, 3, Table 2).
Subfamily OATP2B
This subfamily contains human OATP2B1 [previously
called OATP-B (SLC21A9)] (Figs. 2, 3, Table 2), which
was originally isolated from human brain as a 709-amino-
acid protein [47]. It shows a 77% amino acid sequence
identity with its rat ortholog Oatp2b1 [previously called
Oatp9 (Slc21a9)] [1]. Although human OATP2B1 was
originally cloned from a brain library, its strongest
expression is in the liver, followed by the spleen,
placenta, lung, kidney, heart, ovary, small intestine, and
brain [3, 22, 48]. In addition, OATP2B1 is expressed in
several fetal tissues and in colon adenocarcinoma (CX-1)
cells [3]. In human liver, OATP2B1 is exclusively
expressed at the basolateral (sinusoidal) plasma mem-
brane of hepatocytes and exhibits an apparent molecular
mass of 85 kDa [22]. Thus, besides OATP1B1 and
OATP1B3, OATP2B1 is the third OATP localized at the
sinusoidal membrane of human hepatocytes (Fig. 4).
Functionally, OATP2B1 has been studied in X. laevis
oocytes and in transiently transfected HEK293 cells [3,
22]. Compared to other OATPs it has a narrow substrate
specificity and transports only BSP, estrone-3-sulfate
and dehydroepiandrosterone-sulfate (DHEAS). For other
compounds such as PGE2 and estradiol-17b-glucuronide
controversial results have been presented [1].
Oatp2b1 [49] is the single ortholog of human
OATP2B1 and has been isolated as a multispecific
organic anion transporter from rat brain with similar
function as but broader substrate specificity than
OATP2B1 [1].
Family OATP3
Family OATP3 consists of a single subfamily (OATP3A)
with a total number of three highly homologous individ-
ual genes in man, rat and mouse (Figs. 2, 3).
Subfamily OATP3A
This subfamily contains human OATP3A1 [previously
called OATP-D (SLC21A11)] (Figs. 2, 3, Table 2), which
has been isolated from a human kidney library as a 710-
amino-acid protein [3]. At the amino acid level,
OATP3A1 shows a 97% sequence identity with its rat
and mouse ortholog Oatp3a1 [previously called Oatp11
(Slc21a11)] [1]. Thus, the OATP3A subfamily has been
highly conserved during evolution, which is also docu-
mented by the highly homologous ortholog found in B.
taurus (Fig. 3) and by several highly conserved sequences
obtained when searching the genome databases of various
species. Based on RT-PCR experiments, OATP3A1 is
ubiquitously expressed and has also been detected in
several cancer cell lines [3]. Thus, on the basis of mRNA
expression OATP3A1 exhibits the widest tissue distribu-
tion of all OATPs so far investigated.
The functional transport properties of OATP3A1 have
not been studied extensively. In HEK293 cells transiently
expressing OATP3A1, only estrone-3-sulfate, PGE2 and
benzylpenicillin have been identified as substrates [3].
Despite this limited characterization of its transport
properties, the high degree of amino acid identities within
this subfamily as well as the wide tissue distribution of
OATP3A1 indicate that these gene products might serve
an important physiologic function. A splice variant with a
different C-terminal end (OATP3A1_v2) has been de-
posited in the database (BC000585, Table 2), however, no
functional data are available so far.
Rat and mouse Oatp3a1 have so far only been
identified and deposited in the database as cDNAs
encoding 710-amino-acid proteins (accession numbers:
rat: AF239219; mouse: AF226324).
Family OATP4
Family OATP4 consists of three subfamilies, of which the
two subfamilies OATP4A and OATP4C contain four
individual genes in man, rat and mouse (Figs. 2, 3).
OATP4A
This subfamily contains human OATP4A1 [previously
called OATP-E (SLC21A12)] (Figs. 2, 3, Table 2), which
was isolated from human kidney and brain as a 722-
amino-acid protein [3, 50]. It shows 76% amino acid
sequence identity with its rodent ortholog Oatp4a1
[previously called Oatp12 (Slc21a12)] (Figs. 2, 3,
Table 2). OATP4A1 mRNA is expressed ubiquitously
with strongest expression in liver, heart, placenta and
pancreas [50]. At the protein level it has been localized to
the apical surface of the syncytiotrophoblast [51].
In cRNA-injected X. laevis oocytes OATP4A1 trans-
ported taurocholate and the thyroid hormones T3, T4 and
rT3 [50], while in transiently transfected HEK293 cells
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additional uptake of steroid conjugates, PGE2 and
benzylpenicillin was found [3].
Oatp4a1 [50] was isolated from a rat retina cDNA
library as a 722-amino-acid protein and has so far only
been characterized minimally. It seems to mediate
transport of taurocholate, T3 and PGE2 [50].
Subfamily OATP4C
This subfamily contains human OATP4C1 [previously
called OATP-H (SLC21A20)] (Figs. 2, 3, Table 2), which
is so far the only SLCO gene in this subfamily. Its cDNA
sequence has been deposited in the database. Its func-
tional properties are currently under investigation in our
laboratory.
Family OATP5
Family OATP5 consists of the single subfamily OATP5A
with a single human gene (Figs. 2, 3).
Subfamily OATP5A
This subfamily contains human OATP5A1 [previously
called OATP-J (SLC21A15)] (Figs. 2, 3, Table 2), which
has been isolated and deposited in the database
(NM_030958) as a cDNA encoding a protein of 848
amino acids with unknown transport properties.
Family OATP6
Family OATP6 consists of the four subfamilies OATP6A,
OATP6B, OATP6C and OATP6D, which contain six
individual genes in man, rat and mouse (Figs. 2, 3). Please
note that this family has previously been classified as
OATP10 [1].
Subfamily OATP6A
This subfamily contains human OATP6A1 [previously
called OATP-I (SLC21A19)] (Figs. 2, 3, Table 2), which
has been isolated from human testis but so far no
functional characterization has been published [52].
Subfamily OATP6B
This subfamily contains rat and mouse Oatp6b1 [previ-
ously called GST-1 (Slc21a16)] (Figs. 2, 3, Table 2). Rat
Oatp6b1 has recently been published to be a gonad-
specific transport system for taurocholate, DHEAS and
thyroxine [52]. Mouse Oatp6b1 has been identified as an
OATP-related protein with no functional characterization
so far [53].
Subfamily OATP6C
This subfamily contains the rat gonad-specific organic
anion transporter Oatp6c1 [previously called GST-2
(Slc21a18)] (Figs. 2, 3, Table 2) [52]. Mouse Oatp6c1
has been identified as an OATP-related protein with no
functional characterization so far [53].
Subfamily OATP6D
This subfamily contains a single mouse Oatp6d1 [previ-
ously called Oatp17 (Slc21a17)] (Figs. 2, 3, Table 2) that
was identified as an OATP-related protein with no
functional characterization so far [53].
Conclusions and perspectives
The OATP/SLCO superfamily consists of multi- and
oligospecific membrane transport systems, that mediate
sodium-independent transmembrane solute transport. The
multispecific transporters accept a broad range of amphi-
pathic endo- and xenobiotics. Their multiple expression in
the liver, kidney, small intestine, choroid plexus, blood-
brain barrier and many other tissue barriers puts them into
a strategic position for absorption, distribution and
excretion of xenobiotic substances. Thus, multispecific
Oatps/OATPs are important transporters of the overall
body detoxification system. Alternatively, Oatps/OATPs
with a rather restricted substrate specificity appear to be
more highly conserved during evolution, exhibit a
narrower tissue distribution, and might have important
physiological functions in specific organs.
Although several individual members of the OATP/
SLCO superfamily have been characterized in detail,
numerous questions remain unanswered and require more
thorough investigations in the near future. They include:
(1) the determination of the exact tissue expression of all
individual Oatps/OATPs, (2) the definitive characteriza-
tion of the driving force(s) involved in Oatp/OATP-
mediated substrate transport, (3) a detailed understanding
of the molecular basis of the broad substrate specificity,
(4) the development of specific inhibitors for individual
Oatps/OATPs, (5) investigation of the transcriptional and
post-transcriptional regulation of individual Oatp/OATP
expression, (6) elucidation of interactions of Oatps/
OATPs with other proteins, (7) identification and char-
acterization of gene polymorphisms, and (8) determina-
tion of the overall significance of individual Oatps/
OATPs for physiology, pathophysiology, pharmacology
and toxicology.
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